title: Evaluation of two treatments in superovulation of mares.
abstract: The efficiency of superovulating mares with an enriched fraction of equine follicle-stimulating hormone (feFSH) and an equine pituitary extract (EPE) with similar FSH content but differing in the LH amount was compared. Mares were randomly assigned to an feFSH (n = 5) or EPE (n = 5) treatment. The experimental period was of 2 successive estrous cycles, with the first cycle as the control. At Days 6 and 7 of the estrous cycle, the mares received 250 micrograms i.m. cloprostenol. The treatments consisted of daily injections of 25 mg feFSH or EPE beginning on Day 6 post ovulation. Mares were inseminated every other day until the last ovulation was detected. When the mares in the control and treatment cycles developed at least 1 or 2 > or = 35-mm follicle, respectively, the treatment was interrupted, and a single injection of EPE (25 mg, i.v.) was administered to induce ovulation(s). Nonsurgical embryo recovery was performed 6 or 7 d after ovulation in both control and treatment cycles. The number of ovulations per mare was not significantly different (P > 0.05) between feFSH and EPE groups, but both were higher (P < 0.05) than that of the control cycle. The number of recovered embryos per ovulation was similar (P > 0.05) for control, feFSH and EPE groups. The high amount of LH presented in EPE did not affect the superovulatory response of the mares. Superovulatory treatments increased the ovulation rate of mares but did not affect the embryo recovery rate per ovulation.
authors.affiliation: CENARGEN/EMBRAPA CP 02372 CEP 70.849-970 Brasília-DF, Brasil.
authors.forename: C A
authors.initials: CA
authors.lastname: Rosas
authors.forename: R H
authors.initials: RH
authors.lastname: Alberio
authors.forename: J L
authors.initials: JL
authors.lastname: Barañao
authors.forename: A
authors.initials: A
authors.lastname: Agüero
authors.forename: M G
authors.initials: MG
authors.lastname: Chaves
mesh_terms: D000818:Animals; D003008:Cloprostenol / Q000627:therapeutic use; D004971:Estrus; D005260:Female; D005307:Fertilization in Vitro / Q000662:veterinary*; D005640:Follicle Stimulating Hormone / Q000032:analysis / Q000502:physiology*; D006736:Horses / Q000502:physiology*; D007986:Luteinizing Hormone / Q000032:analysis / Q000502:physiology; D008297:Male; D006080:Ovarian Follicle / Q000502:physiology; D010053:Ovary / Q000000981:diagnostic imaging; D017440:Photoperiod; D010902:Pituitary Gland / Q000737:chemistry / Q000378:metabolism; D011869:Radioligand Assay / Q000662:veterinary; D011897:Random Allocation; D013480:Superovulation / Q000502:physiology*; D014463:Ultrasonography
chemical_list: D003008:Cloprostenol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone